However, since the first description of VEXAS patients in 2021, it seems from numerous case reports that MDS related to VEXAS is different from the MDS described in the classic, it often coexists with MDS, mainly male patients who exhibit unique clinical features of systemic inflammation after the fifth decade of life, as well as haematological abnormalities and precursor cell vacuolization in bone marrow pathology, therefore, genetic changes in the UBA1 gene are now considered to be potentially associated with haematological tumours.6 This evidence concerns the gene UBA1 and myelodysplastic syndrome.